Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navlimetostat plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic MTAP-deleted non-small cell lung cancer
2025-521511-40-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 36
01
Overview
Phase 3, randomised, double-blind trial of navlimetostat in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Progression-free survival and Overall survival. Planned start Nov 2025; status: authorised.
02
Drugs
navlimetostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-521511-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521511-40-00.